# Myocardial and Vascular Involvement in COVID-19 and Post-Vaccination States: Understanding Injury Pathways and Clinical Implications

**Authors:** Roxana-Nicoleta Siliste, Serban Benea, Corina Homentcovschi, Teodora Deaconu, Constantin Caruntu, Ilinca Savulescu-Fiedler

PMC · DOI: 10.3390/life16020268 · 2026-02-04

## TL;DR

This paper explores how SARS-CoV-2 infection and vaccination can cause heart and blood vessel injuries, comparing their mechanisms and clinical outcomes.

## Contribution

The paper provides a synthesis of recent evidence on myocardial and vascular injury mechanisms in both COVID-19 and post-vaccination states.

## Key findings

- Myocardial injury in COVID-19 involves direct viral effects and immune-mediated inflammation.
- Vaccine-associated myocarditis is likely due to immune-related mechanisms and is generally self-limiting.
- The risk of myocarditis from vaccination is much lower than from SARS-CoV-2 infection.

## Abstract

Myocardial and vascular injury secondary to SARS-CoV-2 infection and vaccination has emerged as a clinically relevant phenomenon, with distinct but overlapping mechanisms. Myocardial injury in COVID-19 results from a complex interplay between direct viral effects and immune-mediated inflammation, supported by histopathological studies revealing macrophage-rich infiltrates, microthrombosis, and supporting fibrosis in isolated areas. In contrast, vaccine-associated myocarditis—reported predominantly following mRNA vaccines—has a self-limiting clinical course, with mechanisms likely involving molecular mimicry, aberrant immune activation, or hypersensitivity reactions, although these pathways require further validation. Although mRNA vaccines have been associated with a small increase in myocarditis, particularly in young men, the risk is significantly lower than that associated with COVID-19 infection, and the cardiovascular benefits of vaccination far outweigh these rare adverse events in most populations. After the end of the pandemic, the number of patients with severe forms of COVID-19 has decreased significantly, but we consider that cardiac involvement remains an important issue for the acute and long-term prognosis of patients with SARS-CoV-2 infection. Our paper synthesizes the latest epidemiological and mechanistic evidence on the link between COVID-19, vaccination, and myocardial and/or vascular injuries, highlighting the clinical implications and providing practical recommendations for management, as well as future perspectives on risk assessment, targeted immunotherapy, advanced diagnostic tools, and long-term monitoring.

## Linked entities

- **Diseases:** myocarditis (MONDO:0004496), COVID-19 (MONDO:0100096)

## Full-text entities

- **Genes:** FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, NPPB (natriuretic peptide B) [NCBI Gene 4879] {aka BNP, Iso-ANP}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, PPIA (peptidylprolyl isomerase A) [NCBI Gene 5478] {aka CYPA, CYPH, HEL-S-69p}, Ccl2 (C-C motif chemokine ligand 2) [NCBI Gene 20296] {aka HC11, JE, MCAF, MCP-1, MCP1, SMC-CF}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, AGTR2 (angiotensin II receptor type 2) [NCBI Gene 186] {aka AT2, ATGR2, MRX88}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, F3 (coagulation factor III, tissue factor) [NCBI Gene 14066] {aka CD142, Cf-3, Cf3, TF}, NRP1 (neuropilin 1) [NCBI Gene 8829] {aka BDCA4, CD304, NP1, NRP, VEGF165R}, S (surface glycoprotein) [NCBI Gene 43740568] {aka spike glycoprotein}, VWF (von Willebrand factor) [NCBI Gene 7450] {aka F8VWF, VWD}, Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, CD68 (CD68 molecule) [NCBI Gene 968] {aka GP110, LAMP4, SCARD1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, ACE2 (angiotensin converting enzyme 2) [NCBI Gene 59272] {aka ACEH}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, BSG (basigin (Ok blood group)) [NCBI Gene 682] {aka 5F7, CD147, EMMPRIN, EMPRIN, HAb18G, OK}, KNG1 (kininogen 1) [NCBI Gene 3827] {aka BDK, BK, HAE6, HK, HMWK, KNG}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, MIR208B (microRNA 208b) [NCBI Gene 100126336] {aka MIRN208B, mir-208b}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, ADAM17 (ADAM metallopeptidase domain 17) [NCBI Gene 6868] {aka ADAM18, CD156B, CSVP, HYPT16, NISBD, NISBD1}, AGT (angiotensinogen) [NCBI Gene 183] {aka ANHU, SERPINA8, hFLT1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, AGTR1 (angiotensin II receptor type 1) [NCBI Gene 185] {aka AG2S, AGTR1B, AT1, AT1AR, AT1B, AT1BR}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, DPP4 (dipeptidyl peptidase 4) [NCBI Gene 1803] {aka ADABP, ADCP2, CD26, DPPIV, TP103}, CD14 (CD14 molecule) [NCBI Gene 929], IL1RN (interleukin 1 receptor antagonist) [NCBI Gene 3557] {aka CRMO2, DIRA, ICIL-1RA, IL-1RN, IL-1ra, IL-1ra3}, MPO (myeloperoxidase) [NCBI Gene 4353], FCGR3A (Fc gamma receptor IIIa) [NCBI Gene 2214] {aka CD16-II, CD16A, FCG3, FCGR3, FCRIIIA, FcGRIIIA}, MIR499A (microRNA 499a) [NCBI Gene 574501] {aka MIR499, MIRN499, hsa-mir-499a, mir-499a}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, IL13 (interleukin 13) [NCBI Gene 3596] {aka IL-13, P600}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, AP2B1 (adaptor related protein complex 2 subunit beta 1) [NCBI Gene 163] {aka ADTB2, AP105B, AP2-BETA, CLAPB1}, MIR21 (microRNA 21) [NCBI Gene 406991] {aka MIRN21, hsa-mir-21, miR-21, miRNA21}, MYH14 (myosin heavy chain 14) [NCBI Gene 79784] {aka DFNA4, DFNA4A, FP17425, MHC16, MYH17, NMHC II-C}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, Cxcl15 (C-X-C motif chemokine ligand 15) [NCBI Gene 20309] {aka Il8, Scyb15, lungkine, weche}, NOS3 (nitric oxide synthase 3) [NCBI Gene 4846] {aka EC-NOS, ECNOS, MYMY8, NOSIII, cNOS, eNOS}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}
- **Diseases:** immune-mediated inflammation (MESH:D007249), heart injury (MESH:D006335), vasculitis (MESH:D014657), injury to (MESH:D014947), fibrosis (MESH:D005355), respiratory illness (MESH:D012140), cardiac pain (MESH:D010146), acute Coronary syndrome (MESH:D054058), dyspnea (MESH:D004417), cardiogenic shock (MESH:D012770), inflammatory syndrome (MESH:D018746), motion (MESH:D009041), LGE (MESH:C564835), ischemic (MESH:D002545), endothelial dysfunction (MESH:D014652), diabetes (MESH:D003920), bundle branch block (MESH:D002037), lung injury (MESH:D055370), ventricular dysfunction (MESH:D018754), edema (MESH:D004487), diastolic dysfunction (MESH:D018487), hemorrhage (MESH:D006470), obesity (MESH:D009765), autoimmune (MESH:D001327), necrotic lesions (MESH:D009059), Arrhythmia (MESH:D001145), chest pain (MESH:D002637), Myocardial injury (MESH:D009202), chronic obstructive pulmonary disease (MESH:D029424), Fatigue (MESH:D005221), Myocarditis (MESH:D009205), viral hemorrhagic fevers (MESH:D006482), Pulmonary embolism (MESH:D011655), pericardial effusion (MESH:D010490), hypoxemia (MESH:D000860), bradyarrhythmia (MESH:D001919), pericarditis (MESH:D010493), MIS (MESH:C000705967), thrombosis (MESH:D013927), microvascular thrombosis (MESH:D017566), death (MESH:D003643), Hypertension (MESH:D006973), viral (MESH:D014777), MERS (MESH:D018352), coxsackievirus B3 (OMIM:120050), cardiovascular complications (MESH:D002318), Infection (MESH:D007239), dilated cardiomyopathy (MESH:D002311), right ventricular dysfunction (MESH:D018497), AMI (MESH:D009203), myocardial ischemia (MESH:D017202), immune (MESH:D007154), COVID (MESH:D000086382), atrial fibrillation (MESH:D001281), herpes simplex (MESH:D006561), Myocardial involvement (MESH:C564676), Myocardial and vascular injury (MESH:D057772), capillary leak (MESH:D019559), atrioventricular block (MESH:D054537), pericardial involvement (MESH:D008476)
- **Chemicals:** ibuprofen (MESH:D007052), oxygen (MESH:D010100), testosterone (MESH:D013739), Colchicine (MESH:D003078), prostacyclin (MESH:D011464), NO (MESH:D009569), MCC950 (MESH:C000597426), Canakinumab (MESH:C541220), IL-37 (-), NOs (MESH:D009614), polyunsaturated fatty acids (MESH:D005231), indomethacin (MESH:D007213), peroxynitrite (MESH:D030421), lipid (MESH:D008055), ROS (MESH:D017382)
- **Species:** Zika virus (no rank) [taxon 64320], Mus musculus (house mouse, species) [taxon 10090], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Human immunodeficiency virus 1 (no rank) [taxon 11676], H1N1 subtype (serotype) [taxon 114727], Severe acute respiratory syndrome-related coronavirus (no rank) [taxon 694009], Respiratory syncytial virus (no rank) [taxon 12814], Homo sapiens (human, species) [taxon 9606], Dengue virus (no rank) [taxon 12637], H5N1 subtype (serotype) [taxon 102793], Influenza A virus (no rank) [taxon 11320], Coronaviridae (family) [taxon 11118]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12942253/full.md

---
Source: https://tomesphere.com/paper/PMC12942253